Last updated: November 3, 2026
Requip is the GlaxoSmithKline brand for ropinirole, a dopamine agonist approved in the United States for Parkinson's disease and restless legs syndrome (RLS). Its commercial trajectory followed a conventional small-molecule lifecycle: rapid uptake in Parkinson's disease, expansion into RLS, a reformulated extended-release product, and subsequent erosion after generic entry.
The product is no longer a significant branded revenue asset. Generic ropinirole is widely available, pricing is low, and the remaining commercial opportunity is concentrated in generic immediate-release and extended-release prescriptions rather than the Requip brand.
What is Requip and how is ropinirole used?
Requip contains ropinirole hydrochloride, a non-ergoline dopamine agonist that stimulates dopamine D2-family receptors. The product was developed and commercialized by GlaxoSmithKline, originally through SmithKline Beecham.
| Product |
Active ingredient |
Dosage form |
Primary U.S. indications |
Commercial status |
| Requip |
Ropinirole hydrochloride |
Immediate-release tablets |
Parkinson's disease; moderate-to-severe primary RLS |
Generic competition |
| Requip XL |
Ropinirole hydrochloride |
Extended-release tablets |
Parkinson's disease |
Generic competition |
| Generic ropinirole |
Ropinirole hydrochloride |
Immediate-release and extended-release tablets |
Same or substantially equivalent indications |
Widely available |
The immediate-release product is taken multiple times daily for Parkinson's disease and is titrated according to tolerability and response. Requip XL uses once-daily extended release and was positioned to improve dosing convenience and support more stable plasma exposure. The RLS market broadened ropinirole's use beyond Parkinson's disease, but it also exposed the product to competition from pramipexole, rotigotine, gabapentin enacarbil, and non-drug treatment strategies.
The FDA approved Requip for Parkinson's disease in 1997. The FDA later approved ropinirole for RLS, expanding the addressable patient population. Requip XL received U.S. approval in 2008 for Parkinson's disease treatment (U.S. Food and Drug Administration [FDA], 2008a; FDA, 2008b).
When did Requip lose exclusivity?
Requip lost effective small-molecule exclusivity in the United States through a combination of patent expiry, generic approvals, and the absence of a durable product-level barrier.
The immediate-release franchise entered generic competition in the late 2000s. By the early 2010s, multiple manufacturers supplied ropinirole tablets, and the branded product had lost most of its pricing power.
Requip exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| U.S. approval for Parkinson's disease |
1997 |
Brand launch |
| RLS indication expanded |
2000s |
Increased patient and prescription base |
| Requip XL approval |
2008 |
Lifecycle extension through once-daily dosing |
| Immediate-release generic entry |
Late 2000s |
Rapid erosion of branded volume and price |
| Extended-release generic competition |
2010s |
Reduced remaining differentiation |
| Brand relevance |
Current |
Limited; market is primarily generic |
The exact loss date differed by dosage form and patent claim. Immediate-release ropinirole faced generic competition earlier than Requip XL. The practical commercial cliff occurred when generic manufacturers could supply the major strengths used in routine clinical practice.
What patents protected Requip?
The original Requip estate covered ropinirole chemistry, pharmaceutical compositions, and methods of treatment. Later filings addressed extended-release delivery and formulation characteristics.
Core patent categories
| Patent category |
Protected subject matter |
Strategic value |
| Compound patents |
Ropinirole and related chemical structures |
Created the original exclusivity period |
| Salt and composition patents |
Ropinirole hydrochloride and pharmaceutical compositions |
Supported drug-product protection |
| Method-of-use patents |
Treatment of Parkinson's disease and RLS |
Added indication-specific protection |
| Extended-release formulation patents |
Controlled release of ropinirole |
Supported Requip XL lifecycle management |
| Manufacturing patents |
Preparation, purification, or formulation processes |
Limited value after alternative processes became available |
The original chemical and composition protection was the principal commercial barrier. Method-of-use patents had weaker practical value because physicians could prescribe generic ropinirole for approved uses and generic applicants could use certification strategies under the Hatch-Waxman framework.
Requip XL created a more technically differentiated product, but its protection was still limited by the availability of alternative extended-release formulations and the ability of generic companies to challenge or design around formulation claims.
How strong was the Requip patent estate?
The estate was commercially effective during the first product cycle but is weak as a current barrier.
Its historical strength came from:
- A first-in-class or early-entry position in dopamine agonist therapy.
- A protected active pharmaceutical ingredient.
- A large Parkinson's disease prescription base.
- A later extended-release formulation.
- A separate RLS indication that supported market expansion.
Its weaknesses were equally important:
- Ropinirole is a conventional small molecule with no biologic manufacturing barrier.
- The active ingredient can be manufactured by multiple suppliers.
- Generic substitution is straightforward for immediate-release tablets.
- Formulation protection did not prevent long-term generic substitution.
- The therapeutic class had competing agents with different dosing and adverse-event profiles.
The current U.S. market therefore has little practical exposure to an enforceable branded patent barrier. The original product patents and key formulation protections are no longer sufficient to preserve a meaningful branded franchise.
What is the Orange Book status of Requip?
Requip and Requip XL were listed in the FDA Orange Book under separate new drug applications. The relevant regulatory framework included listed patents, pediatric-exclusivity information where applicable, and abbreviated new drug applications for generic ropinirole.
The Orange Book's commercial significance was greatest before generic entry. Once generic manufacturers obtained approvals for the relevant strengths and dosage forms, listed patents no longer prevented broad substitution.
FDA and Orange Book considerations
For Requip, the principal issues were:
- Whether a generic applicant could obtain approval for the same immediate-release strengths.
- Whether extended-release products were sufficiently equivalent to Requip XL.
- Whether listed patents required Paragraph IV certification.
- Whether any pediatric or regulatory exclusivity delayed approval.
- Whether formulation differences affected substitution and prescribing.
The product does not have the regulatory profile of a biologic. Generic approval proceeds through an ANDA rather than a biosimilar application. There is no meaningful biosimilar risk for Requip because ropinirole is a chemically synthesized small molecule.
Which companies challenged Requip patents?
Generic manufacturers, including large suppliers of oral solid-dose medicines, entered the ropinirole market after the primary exclusivity period. Public commercial evidence indicates that the material threat came from ANDA competition rather than from a prolonged, franchise-defining patent dispute.
Paragraph IV challenges were relevant to the timing of generic entry, particularly for products associated with extended-release formulations. Under the Hatch-Waxman system, an ANDA applicant may certify that a listed patent is invalid, unenforceable, or not infringed. A Paragraph IV certification can trigger litigation and a potential 30-month stay of FDA approval.
The Requip franchise did not retain a commercially meaningful barrier after generic manufacturers obtained approvals across the principal strengths. Any historical litigation was therefore less important than the eventual breadth of generic approvals and pharmacy substitution.
What formulations are protected by Requip patents?
The two commercially important formulations were immediate-release tablets and extended-release tablets.
Immediate-release ropinirole
Immediate-release tablets were the primary generic-entry target. Their technical characteristics are comparatively simple:
- Conventional oral tablet manufacturing.
- Multiple dose strengths.
- Straightforward active-ingredient equivalence testing.
- Limited formulation differentiation.
- High substitutability after approval.
This format experienced the fastest and most complete erosion.
Requip XL extended-release tablets
Requip XL used a controlled-release design intended to provide once-daily dosing. Extended-release formulations can create additional patent opportunities because protection may cover:
- Release-rate profiles.
- Matrix or coating systems.
- Tablet composition.
- Pharmacokinetic parameters.
- Food-effect limitations.
- Manufacturing processes.
Those claims can delay or complicate generic entry, but they do not create the same durable barrier as a novel chemical entity patent. Generic developers can challenge the claims, develop alternative release technologies, or enter after expiration.
How did Requip sales develop over time?
Requip's revenue curve had four stages:
- Launch and indication expansion. Sales increased as Parkinson's disease use grew and the RLS indication expanded the patient base.
- Maturity. The brand became an established dopamine agonist but faced competition from pramipexole and other therapies.
- Lifecycle management. Requip XL attempted to retain patients through once-daily dosing and extended-release technology.
- Generic erosion. Immediate-release generic entry reduced price, market share, and branded revenue. Later generic competition weakened the extended-release opportunity.
GlaxoSmithKline's annual reports historically reported Requip as part of its prescription pharmaceutical portfolio. As generic competition intensified, Requip ceased to be a material standalone growth driver and was no longer a meaningful contributor to the company's overall financial trajectory (GlaxoSmithKline, 2007-2012).
Financial trajectory
| Period |
Revenue condition |
Main driver |
| Late 1990s |
Growth |
Parkinson's disease launch |
| Early-to-mid 2000s |
Expansion |
RLS indication and broader physician adoption |
| Late 2000s |
Peak-to-decline transition |
Generic immediate-release entry |
| Early 2010s |
Sharp erosion |
Generic substitution and price compression |
| Current |
Low-value generic market |
Commodity oral solid-dose supply |
The financial impact was concentrated in the transition from branded pricing to generic pricing. Prescription volume did not need to disappear for revenue to collapse. A substantial portion of prescriptions could remain in the category while manufacturer revenue declined because generic prices were materially lower and pharmacy substitution redirected volume away from the brand.
What generic entry risks affected Requip?
The most important generic-entry risks were:
- Immediate-release tablet substitution.
- Multiple generic suppliers competing on price.
- Loss of preferred formulary placement.
- Pharmacy-level automatic substitution.
- Declining physician incentive to prescribe the brand.
- Reduced ability to use coupons or contracting to preserve share.
- Extended-release alternatives that weakened Requip XL's differentiation.
The risk profile was higher for immediate-release Requip because the dosage form was easy to replicate. Requip XL had greater technical complexity, but once an equivalent extended-release product became available, the brand's pricing advantage also weakened.
A generic launch scenario for a branded Requip product would typically involve rapid prescription migration in high-volume strengths, followed by continued price declines as additional suppliers enter. The brand may retain limited use where physicians prefer the original product, patients report differences between formulations, or payer policies do not require substitution. Those segments are insufficient to support historical revenue levels.
How does Requip compare with competing dopamine agonists?
| Product |
Active ingredient |
Differentiation |
Generic status |
Commercial implication |
| Requip |
Ropinirole |
Immediate-release and extended-release oral dosing; RLS approval |
Generic |
Mature, price-driven market |
| Mirapex |
Pramipexole |
Parkinson's disease and RLS use |
Generic |
Direct therapeutic substitute |
| Neupro |
Rotigotine |
Transdermal patch |
Branded and generic competition in some markets |
Differentiated delivery system |
| Parlodel |
Bromocriptine |
Older dopamine agonist |
Generic |
Lower-cost legacy option |
| Xadago and other adjunctive therapies |
Different mechanisms |
Add-on treatment rather than direct replacement |
Mixed |
Competitive pressure on Parkinson's treatment share |
Requip's strongest competitive advantage was its established clinical use and RLS indication. Its weakest point was the lack of a durable delivery-system advantage in the main immediate-release franchise.
Rotigotine's transdermal delivery created a different adherence and tolerability proposition. Pramipexole was the closest oral competitor. Once both ropinirole and pramipexole became generic, treatment selection increasingly depended on patient response, adverse effects, dosing convenience, payer preference, and physician familiarity rather than brand differentiation.
What licensing deals affected Requip?
Requip was developed and commercialized within GlaxoSmithKline's predecessor-company structure rather than through a widely reported later-stage licensing transaction comparable to many specialty medicines.
The commercial rights were primarily controlled through GSK's internal pharmaceutical organization. There is no major current licensing structure that materially changes the global economics of ropinirole. In some countries, local distributors or generic manufacturers may hold marketing authorizations, but these arrangements do not recreate the historical U.S. branded value.
What geographic markets still matter?
Ropinirole is available as a generic in major pharmaceutical markets, including the United States and Europe. Geographic value is determined by:
- Generic penetration.
- National reimbursement rules.
- Reference pricing.
- Pharmacy substitution.
- Local regulatory approval.
- Manufacturing costs.
- Hospital versus retail channel mix.
The United States experienced strong substitution pressure because of the scale of generic dispensing and payer controls. European markets also experienced substantial price erosion, although the timing and magnitude varied by country. Emerging markets may retain multiple local manufacturers, but revenue per prescription is generally much lower than during the U.S. branded period.
Manufacturing is not a major strategic barrier. Ropinirole is a chemically synthesized small molecule supplied through conventional active-pharmaceutical-ingredient and tablet-manufacturing networks. The main barriers are regulatory compliance, bioequivalence, quality systems, and distribution scale.
What is the current commercial outlook for Requip?
The current outlook is that Requip has residual brand recognition but limited branded economic value. Generic ropinirole is the dominant commercial product.
The market is likely to remain stable in volume but competitive in price. Demand is supported by the chronic nature of Parkinson's disease and RLS. Revenue growth is constrained by:
- Generic substitution.
- Mature treatment guidelines.
- Competing dopamine agonists.
- Increased use of non-dopaminergic RLS treatments.
- Safety concerns associated with dopamine agonists, including somnolence, impulse-control disorders, and augmentation in RLS.
- Limited opportunity for premium reformulation.
The product's residual value is concentrated in generic manufacturing, supply reliability, selected international markets, and portfolio-scale economics. It is not a credible standalone branded growth asset.
Key Takeaways
- Requip is the GSK brand for ropinirole hydrochloride.
- The product was approved for Parkinson's disease in 1997 and later expanded into RLS.
- Requip XL used extended-release technology as a lifecycle-management strategy.
- Immediate-release generic competition emerged in the late 2000s.
- The brand's revenue declined sharply after generic entry and price substitution.
- Ropinirole has no biosimilar risk because it is a small-molecule drug.
- Current patent protection does not create a meaningful U.S. branded barrier.
- The main commercial market is generic immediate-release and extended-release ropinirole.
- Future value is concentrated in low-cost manufacturing, regulatory approvals, and supply execution rather than patent-protected pricing.
FAQs
Is Requip still sold in the United States?
The active ingredient, ropinirole, remains widely available as a generic. The historical Requip brand has limited commercial significance compared with generic products.
Is ropinirole the same as Requip?
Yes. Requip is the branded product, while ropinirole hydrochloride is the active ingredient supplied by generic manufacturers.
Does Requip still have patent protection?
The original patent estate supported historical exclusivity, but expired or exhausted protection no longer prevents broad generic competition in the United States.
Are there generic versions of Requip XL?
Generic extended-release ropinirole products have entered the market in relevant jurisdictions, reducing the commercial value of the Requip XL brand.
What replaced Requip for restless legs syndrome?
Treatment may involve generic ropinirole, pramipexole, rotigotine, gabapentin enacarbil, pregabalin, or other approaches selected according to symptoms, adverse effects, and clinical guidance.
References
-
GlaxoSmithKline. (2007-2012). Annual reports and financial statements. GlaxoSmithKline plc.
-
U.S. Food and Drug Administration. (1997). Requip approval information and prescribing information. FDA.
-
U.S. Food and Drug Administration. (2008a). Requip XL approval information. FDA.
-
U.S. Food and Drug Administration. (2008b). Ropinirole prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drug database. FDA.
